These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 16062095)
1. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Ko YH; Joe SH; Jung IK; Kim SH Clin Neuropharmacol; 2005; 28(4):169-75. PubMed ID: 16062095 [TBL] [Abstract][Full Text] [Related]
2. Topiramate's effectiveness on weight reduction in overweight/obese persons with schizophrenia: study protocol for a randomized controlled trial. Chandradasa M; Champika L; de Silva S; Kuruppuarachchi KALA Trials; 2017 Sep; 18(1):435. PubMed ID: 28931411 [TBL] [Abstract][Full Text] [Related]
3. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate. Lin YH; Liu CY; Hsiao MC Psychiatry Clin Neurosci; 2005 Oct; 59(5):613-5. PubMed ID: 16194268 [TBL] [Abstract][Full Text] [Related]
4. Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials. Correll CU; Maayan L; Kane J; Hert MD; Cohen D J Clin Psychiatry; 2016 Jun; 77(6):e746-56. PubMed ID: 27337425 [TBL] [Abstract][Full Text] [Related]
5. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Narula PK; Rehan HS; Unni KE; Gupta N Schizophr Res; 2010 May; 118(1-3):218-23. PubMed ID: 20207521 [TBL] [Abstract][Full Text] [Related]
6. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179 [TBL] [Abstract][Full Text] [Related]
7. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. Afshar H; Roohafza H; Mousavi G; Golchin S; Toghianifar N; Sadeghi M; Talaei M J Psychopharmacol; 2009 Mar; 23(2):157-62. PubMed ID: 18515465 [TBL] [Abstract][Full Text] [Related]
8. Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study. Bahk WM; Shin YC; Woo JM; Yoon BH; Lee JS; Jon DI; Chung SK; Choi SK; Paik IH; Pae CU Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):115-21. PubMed ID: 15610953 [TBL] [Abstract][Full Text] [Related]
9. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981 [TBL] [Abstract][Full Text] [Related]
10. The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. Ghanizadeh A; Nikseresht MS; Sahraian A Schizophr Res; 2013 Jun; 147(1):110-115. PubMed ID: 23583010 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115 [TBL] [Abstract][Full Text] [Related]
13. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317 [TBL] [Abstract][Full Text] [Related]
14. A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Roy Chengappa K; Kupfer DJ; Parepally H; John V; Basu R; Buttenfield J; Schlicht P; Houck P; Brar JS; Gershon S Bipolar Disord; 2007 Sep; 9(6):609-17. PubMed ID: 17845276 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311 [TBL] [Abstract][Full Text] [Related]
16. [Effect of Topiramate on Drug Associated Weight Gain of Patients with Schizophrenia and Bipolar I Disorders: A Dose Ranging Randomized Trial]. Talaeı A; Farıdhosseını F; Kazemı H; Fayyazı Bordbar MR; Rezaeı Ardanı A Turk Psikiyatri Derg; 2016; 27(2):0. PubMed ID: 27370059 [TBL] [Abstract][Full Text] [Related]
17. Effect of topiramate augmentation in chronic schizophrenia: a placebo-controlled trial. Behdani F; Hebrani P; Rezaei Ardani A; Rafee E Arch Iran Med; 2011 Jul; 14(4):270-5. PubMed ID: 21726104 [TBL] [Abstract][Full Text] [Related]
18. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. McElroy SL; Frye MA; Altshuler LL; Suppes T; Hellemann G; Black D; Mintz J; Kupka R; Nolen W; Leverich GS; Denicoff KD; Post RM; Keck PE Bipolar Disord; 2007 Jun; 9(4):426-34. PubMed ID: 17547588 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. Zheng W; Xiang YT; Xiang YQ; Li XB; Ungvari GS; Chiu HF; Correll CU Acta Psychiatr Scand; 2016 Nov; 134(5):385-398. PubMed ID: 27585549 [TBL] [Abstract][Full Text] [Related]
20. [Effects of Topiramate for atypical antipsychotic-induced body weight gain and metabolic adversities: a systematic review and meta-analysis]. Liang H; Li H; Hu Y; Li S; Lü L; Song X Zhonghua Yi Xue Za Zhi; 2016 Jan; 96(3):216-23. PubMed ID: 26879726 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]